Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-017811
Filing Date
2022-11-14
Accepted
2022-11-14 16:45:40
Documents
58
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20220930x10q.htm   iXBRL 10-Q 1228399
2 EX-10.1 tmb-20220930xex10d1.htm EX-10.1 150521
3 EX-31.1 tmb-20220930xex31d1.htm EX-31.1 10602
4 EX-31.2 tmb-20220930xex31d2.htm EX-31.2 10450
5 EX-32.1 tmb-20220930xex32d1.htm EX-32.1 6684
6 EX-32.2 tmb-20220930xex32d2.htm EX-32.2 6361
  Complete submission text file 0001558370-22-017811.txt   5040204

Data Files

Seq Description Document Type Size
7 EX-101.SCH tmb-20220930.xsd EX-101.SCH 32564
8 EX-101.CAL tmb-20220930_cal.xml EX-101.CAL 33870
9 EX-101.DEF tmb-20220930_def.xml EX-101.DEF 131610
10 EX-101.LAB tmb-20220930_lab.xml EX-101.LAB 317498
11 EX-101.PRE tmb-20220930_pre.xml EX-101.PRE 236783
52 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20220930x10q_htm.xml XML 807225
Mailing Address 375 PHEASANT RUN NEWTOWN PA 18940
Business Address 375 PHEASANT RUN NEWTOWN PA 18940 267-759-3681
Onconova Therapeutics, Inc. (Filer) CIK: 0001130598 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36020 | Film No.: 221386857
SIC: 2834 Pharmaceutical Preparations